Combination Chemotherapy in Treating Adults With Acute Lymphocytic Leukemia
Unknown status
Johann Wolfgang Goethe University Hospital
Phase 2
1993-01-01
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. Combining more than one drug may kill more cancer cells.
PURPOSE: Randomized phase II trial to study the effectiveness of various combination
chemotherapy regimens in treating patients with acute lymphocytic leukemia.
Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma
Completed
Children's Hospital Medical Center, Cincinnati
Phase 3
1990-07-01
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow
the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Radiation
therapy uses high-energy x-rays to damage tumor cells. It is not yet known which treatment
regimen is most effective in treating patients with different stages of and risk factors for
neuroblastoma.
PURPOSE: Phase III trial to study the effectiveness of therapy based on stage of disease and
risk assessment in treating children with neuroblastoma.
Combination Chemotherapy, Bone Marrow or Peripheral Stem Cell Transplantation, and/or Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma
Completed
National Cancer Institute (NCI)
Phase 2
1999-10-01
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. Combining chemotherapy with peripheral stem cell or bone marrow
transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more
cancer cells. Biological therapies use different ways to stimulate the immune system and stop
cancer cells from growing.
PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by
bone marrow or peripheral stem cell transplantation and/or biological therapy in treating
patients who have stage III, stage IV, or recurrent mantle cell lymphoma.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
